Headquarters of Bayer’s division Pharmaceuticals in Berlin, Germany. Credit: © Bayer AG.

German firms Evotec and Bayer have agreed to expand their alliance to develop drug candidates for polycystic ovary syndrome (PCOS).

PCOS is an endocrine disorder associated with metabolic dysfunction that can cause pregnancy complications and infertility.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The two companies entered a five-year, multi-target collaboration that also includes Celmatix, a medicine firm focusing on women’s health and fertility.

The alliance can also access data-driven target identification from the previously formed partnership between Celmatix and Evotec.

Under the alliance, Bayer and Evotec will share responsibilities for the pre-clinical development of potential candidates.

Bayer will be entitled to carry out subsequent clinical development and commercialisation of the candidates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In turn, Evotec will receive an upfront payment of €6.5m and additional €10m as research payments over five years. It will share the amount with Celmatix.

Subsequently, Evotec and Celmatix can earn more than €330m through milestone payments, apart from royalties on net sales.

Evotec chief scientific officer Dr Cord Dohrmann said: “Polycystic ovary syndrome is a common, underdiagnosed and undertreated disease among women, with several serious co-morbidities. The currently available treatment options are also limited and insufficient.

“Our long-term partnership with Bayer and the progression of multiple clinical candidates have been very successful and we look forward to continuing the relationship to deliver novel therapies for the benefit of patients with PCOS.”

The latest deal builds on Bayer and Evotec first five-year strategic partnership signed in 2012, followed by another research alliance in 2016 to develop clinical candidates for kidney diseases.